(Q43938023)

English

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells (English)

1 reference

Europe PubMed Central

28 November 2017

1 reference

based on heuristic

inferred from title

multiple drug resistance

1 reference

based on heuristic

inferred from title

Fortunato Ciardiello

1

1 reference

Europe PubMed Central

28 November 2017

Annamaria Biroccio

5

1 reference

Europe PubMed Central

28 November 2017

Giampaolo Tortora

8

1 reference

Europe PubMed Central

28 November 2017

Donatella Del Bufalo

object named as

Donatella Del Bufalo

4

0 references

author name string

Rosa Caputo

2

1 reference

Europe PubMed Central

28 November 2017

Gaetano Borriello

3

1 reference

Europe PubMed Central

28 November 2017

Gabriella Zupi

6

1 reference

Europe PubMed Central

28 November 2017

A Raffaele Bianco

7

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 March 2002

1 reference

Europe PubMed Central

28 November 2017

International Journal of Cancer

1 reference

Europe PubMed Central

28 November 2017

98

1 reference

Europe PubMed Central

28 November 2017

3

1 reference

Europe PubMed Central

28 November 2017

463-469

1 reference

Europe PubMed Central

28 November 2017

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Dysregulation of apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Epidermal growth factor receptor family and chemosensitization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.10230

21 January 2018

Identifiers

10.1002/IJC.10230

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43938023&oldid=2123463454"